Amylyx Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
123
- Stock Symbol
-
AMLX
- Investments
-
1
- Share Price
-
$5.36
- (As of Friday Closing)
Amylyx General Information
Description
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Contact Information
Website
www.amylyx.comCorporate Office
- 43 Thorndike Street
- Cambridge, MA 02141
- United States
Corporate Office
- 43 Thorndike Street
- Cambridge, MA 02141
- United States
Amylyx Stock Performance
As of 25-Apr-2025, Amylyx’s stock price is $5.36. Its current market cap is $477M with 89.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.36 | $5.24 | $1.57 - $7.27 | $477M | 89.1M | 807K | -$4.43 |
Amylyx Financials Summary
As of 31-Dec-2024, Amylyx has a trailing 12-month revenue of $87.4M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 27,283 | 27,283 | 643,584 | 2,292,332 |
| Revenue | 87,371 | 87,371 | 380,786 | 22,230 |
| EBITDA | (315,041) | (315,041) | 39,230 | (201,405) |
| Net Income | (301,743) | (301,743) | 49,271 | (198,375) |
| Total Assets | 193,634 | 193,634 | 517,454 | 391,453 |
| Total Debt | 1,981 | 1,981 | 4,237 | 6,277 |
Amylyx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Amylyx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Amylyx Comparisons
Industry
Financing
Details
Amylyx Competitors (9)
One of Amylyx’s 9 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Biohaven | Formerly VC-backed | Tortola, VI | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA |
Amylyx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amylyx Patents
Amylyx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250032514-A1 | Compositions and methods for the treatment of various diseases | Pending | 25-Jul-2023 | ||
| US-20240139211-A1 | Methods and compositions for treating amyotrophic lateral sclerosis | Pending | 29-Sep-2022 | ||
| US-20240100069-A1 | Methods and compositions for treating amyotrophic lateral sclerosis | Pending | 07-Sep-2022 | ||
| AU-2023311008-A1 | Oligonucleotide compositions and methods thereof | Pending | 21-Jul-2022 | ||
| US-20240102018-A1 | Oligonucleotide compositions and methods thereof | Pending | 21-Jul-2022 | C12N15/113 |
Amylyx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amylyx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Amylyx Investments (1)
Amylyx’s most recent deal was a Corporate Asset Purchase with Eiger BioPharmaceuticals (Patent Right of Avexitide) for . The deal was made on 09-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eiger BioPharmaceuticals (Patent Right of Avexitide) | 09-Jul-2024 | Corporate Asset Purchase | Buildings and Property |
Amylyx ESG
Risk Overview
Risk Rating
Updated August, 31, 2023
33.79 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Pharmaceuticals
Subindustry
of 430
Rank
Percentile
Amylyx FAQs
-
When was Amylyx founded?
Amylyx was founded in 2013.
-
Where is Amylyx headquartered?
Amylyx is headquartered in Cambridge, MA.
-
What is the size of Amylyx?
Amylyx has 123 total employees.
-
What industry is Amylyx in?
Amylyx’s primary industry is Drug Discovery.
-
Is Amylyx a private or public company?
Amylyx is a Public company.
-
What is Amylyx’s stock symbol?
The ticker symbol for Amylyx is AMLX.
-
What is the current stock price of Amylyx?
As of 25-Apr-2025 the stock price of Amylyx is $5.36.
-
What is the current market cap of Amylyx?
The current market capitalization of Amylyx is $477M.
-
What is Amylyx’s current revenue?
The trailing twelve month revenue for Amylyx is $87.4M.
-
Who are Amylyx’s competitors?
Alnylam Pharmaceuticals, Biohaven, Cognition Therapeutics, Biogen, and Apellis Pharmaceuticals are some of the 9 competitors of Amylyx.
-
What is Amylyx’s annual earnings per share (EPS)?
Amylyx’s EPS for 12 months was -$4.43.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
